This innovative design, involving inflammation‐guided precise drug co‐delivery and a rational combination, achieves synergistic engineering of the tumor microenvironment, providing a novel strategy for successful PD‐1 treatment of MSS‐CRC. This evidence concerns the gene PDCD1 and neoplasm.